Key result
Cardiogenic shock incidence has risen to approximately 6% to 10% of all STEMI cases, with 6-month mortality rates persistently approaching 50% despite modern therapies.
Answers are grounded in this paper and cite their sources.
Cardiogenic shock remains a major clinical challenge with rising incidence and persistently high mortality around 50% at 6 months.
C ardiogenic shock (CGS) remains a significant clinical prob- lem in cardiovascular medicine.Although history shows event rates have improved, they remain substantial.In 1942, the observations of Stead 1 of shock syndrome resulting from failure of the heart were published, and death at this time in CGS was expected, that is, it was reported at 100%.Goldberg et al 2 in 1977 to 1985 reported in-hospital mortality rates from CGS of 74% to 81%.Since the introduction of early percutaneous coronary intervention (P-PCI) for ST-segment-elevation myocardial infarction (STEMI), there has been a reduction in mortality from CGS.Even so, in the SHOCK trial (Should we Emergently Revascularise Occluded arteries for Cardiogenic Shock), the 30-day mortality of CGS patients randomized to early revascularization was 46.7%, 3 and it has not changed in the past 16 years despite further pharmacological development (such as the TRIUMPH study 4 [A Phase III International, Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition With Tilarginine Acetate Injection in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction] testing the inducible nitric oxide synthase inhibitor tilarginine) and the introduction and testing of devices to support the myocardium such as the Intra Aortic Balloon Pump (eg, as in the IABP-II study 5 [Intra-Aortic Balloon Pump]).Indeed to add to the problem, there have been data to suggest that CGS rates are rising.Kolte et al 6 reported in 2014 that among 1,990,486 reviewed patients, the incidence of CGS rose from 6.5% in 2003 to 10.1% in 2010, which is likely to be because of improvements in very early mortality associated with P-PCI.Further insights come from Kunadian et al,7 who analyzed the data from the UK British Cardiovascular Intervention Society (BCIS) National Cardiovascular Outcomes Research (NICOR) database and also reported that the incidence of CGS rose progressively from 2005 to 2010, with their most recent data from 2014 suggesting an incidence of 11.8% for all acute coronary syndrome patients.However, the incidence will reflect the patient population being examined, and some registry data have found lower rates than these.Irrespective of incidence, most published data indicate that 6 monthly mortality rates commonly approach 50%.At an approximate incidence of 6% to 10% of all STEMI and a mortality rate of 50% at 6 months, it is clear that CGS remains a real problem.
No takes yet. Share an insight, caveat, or question.
Gershlick et al. (2017) conducted an editorial in Cardiogenic shock. Cardiogenic shock incidence has risen to approximately 6% to 10% of all STEMI cases, with 6-month mortality rates persistently approaching 50% despite modern therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: